icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
0JSts9WEj4YU9AHa